| Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte P Feugier, A Van Hoof, C Sebban, P Solal-Celigny, R Bouabdallah, ... Journal of clinical oncology 23 (18), 4117-4126, 2005 | 1913 | 2005 |
| Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial G Salles, JF Seymour, F Offner, A López-Guillermo, D Belada, L Xerri, ... The Lancet 377 (9759), 42-51, 2011 | 1253 | 2011 |
| Treatment of older patients with mantle-cell lymphoma HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ... New England Journal of Medicine 367 (6), 520-531, 2012 | 641 | 2012 |
| Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients M Leporrier, S Chevret, B Cazin, N Boudjerra, P Feugier, B Desablens, ... Blood, The Journal of the American Society of Hematology 98 (8), 2319-2325, 2001 | 551 | 2001 |
| Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study C Charlier, É Perrodeau, A Leclercq, B Cazenave, B Pilmis, B Henry, ... The Lancet Infectious Diseases 17 (5), 510-519, 2017 | 515 | 2017 |
| Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger … O Hermine, E Hoster, J Walewski, A Bosly, S Stilgenbauer, C Thieblemont, ... The Lancet 388 (10044), 565-575, 2016 | 457 | 2016 |
| Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma S Le Gouill, C Thieblemont, L Oberic, A Moreau, K Bouabdallah, ... New England Journal of Medicine 377 (13), 1250-1260, 2017 | 426 | 2017 |
| Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study G Salles, N Mounier, S de Guibert, F Morschhauser, C Doyen, JF Rossi, ... Blood, The Journal of the American Society of Hematology 112 (13), 4824-4831, 2008 | 409 | 2008 |
| Rituximab plus lenalidomide in advanced untreated follicular lymphoma F Morschhauser, NH Fowler, P Feugier, R Bouabdallah, H Tilly, ... New England Journal of Medicine 379 (10), 934-947, 2018 | 360 | 2018 |
| Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular … C Sebban, N Mounier, N Brousse, C Belanger, P Brice, C Haioun, H Tilly, ... Blood 108 (8), 2540-2544, 2006 | 310 | 2006 |
| Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma L Vercellino, R Di Blasi, S Kanoun, B Tessoulin, C Rossi, M D'Aveni-Piney, ... Blood advances 4 (22), 5607-5615, 2020 | 300 | 2020 |
| Incidence and risk factors for central nervous system occurrencein elderly patients with diffuse large-B-cell lymphoma: influenceof rituximab P Feugier, JM Virion, H Tilly, C Haioun, G Marit, M Macro, D Bordessoule, ... Annals of Oncology 15 (1), 129-133, 2004 | 295 | 2004 |
| Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome B Chetaille, F Bertucci, P Finetti, B Esterni, A Stamatoullas, JM Picquenot, ... Blood, The Journal of the American Society of Hematology 113 (12), 2765-3775, 2009 | 264 | 2009 |
| Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study FA Morschhauser, G Cartron, C Thieblemont, P Solal-Céligny, C Haioun, ... Journal of Clinical Oncology 31 (23), 2912-2919, 2013 | 245 | 2013 |
| Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study E Bachy, JF Seymour, P Feugier, F Offner, A López-Guillermo, D Belada, ... Journal of Clinical Oncology 37 (31), 2815-2824, 2019 | 237 | 2019 |
| A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts S Huet, B Tesson, JP Jais, AL Feldman, L Magnano, E Thomas, ... The Lancet Oncology 19 (4), 549-561, 2018 | 213 | 2018 |
| Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With … J Dupuis, A Berriolo-Riedinger, A Julian, P Brice, C Tychyj-Pinel, H Tilly, ... Journal of clinical oncology 30 (35), 4317-4322, 2012 | 210 | 2012 |
| Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial C Sarkozy, M Trneny, L Xerri, N Wickham, P Feugier, S Leppa, P Brice, ... Journal of Clinical Oncology 34 (22), 2575-2582, 2016 | 195 | 2016 |
| Primary lymphoma of the liver: clinical‐pathological features and relationship with HCV infection in French patients JP Bronowicki, C Bineau, P Feugier, O Hermine, N Brousse, F Oberti, ... Hepatology 37 (4), 781-787, 2003 | 195 | 2003 |
| Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study C Sebban, P Brice, R Delarue, C Haioun, B Souleau, N Mounier, ... Journal of Clinical Oncology 26 (21), 3614-3620, 2008 | 183 | 2008 |
